Literature DB >> 6487371

A novel biologically active seleno-organic compound--II. Activity of PZ 51 in relation to glutathione peroxidase.

A Wendel, M Fausel, H Safayhi, G Tiegs, R Otter.   

Abstract

The anti-inflammatory compound 2-phenyl-1,2-benzoisoselenazol-3(2H)-on (PZ 51) catalysed GSSG formation from GSH in the presence of hydroperoxides in an NADPH/GSSG reductase system with the following rates (delta log GSH/min per molar selenium): 1.1 X 10(6) with H2O2, 1.2 X 10(6) with butylhydroperoxide, 1.7 X 10(6) with cumenehydroperoxide. The reaction catalysed by the sulphur analogue of PZ 51 was negligible. Similar results were obtained in a direct assay of GSH-Px activity based on GSH estimation by dithionitrobenzoate. The activation energy of the reaction was determined as 55 kJ/mol . deg in the presence of 30 mumol/1 PZ 51 compared to 36.5 kJ/mol . deg obtained in the presence of 1 nmol/1 pure GSH-Px isolated from bovine red blood cells. In mouse liver microsomes, NADPH-dependent aminopyrine dealkylation was totally inhibited in the presence of 50 mumol/1 PZ 51. In vivo experiments with Se-deficient mice showed that the Se-moiety of PZ 51 is not available for the synthesis of the selenoenzyme GSH-Px after dietary treatment or i.p. doses up to 25 mg Se as PZ 51 per kg body wt. After oral administration of labelled PZ 51, unlike with selenite, no radioactivity was incorporated into GSH-Px within 48 hr. The data suggest that several similarities between PZ 51 and the active site of GSH-Px exist, resulting in the capability of the compound to catalyse the GSH-Px reaction. An extracellular pharmacodynamic action of the drug seems likely.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6487371     DOI: 10.1016/0006-2952(84)90084-4

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  44 in total

1.  Determination of ebselen-sensitive reactive oxygen metabolites (ebROM) in human serum based upon N,N'-diethyl-1,4-phenylenediamine oxidation.

Authors:  Yongliang Liang; James R Roede; Sergey Dikalov; Nana Gletsu Miller; Samuel C Dudley; Arshed Quyyumi; Dean P Jones
Journal:  Clin Chim Acta       Date:  2012-06-08       Impact factor: 3.786

Review 2.  The pharmacology of ebselen.

Authors:  M J Parnham; S Leyck; E Graf; E J Dowling; D R Blake
Journal:  Agents Actions       Date:  1991-01

3.  Selective inhibition of leukotriene B4 formation by Ebselen: a novel approach to antiinflammatory therapy.

Authors:  P Kuhl; H O Borbe; A Römer; H Fischer; M J Parnham
Journal:  Agents Actions       Date:  1986-01

4.  Progress does not just come in giant leaps: adapting techniques for the study of inflammation to novel applications.

Authors:  Michael J Parnham
Journal:  Inflamm Res       Date:  2016-09-28       Impact factor: 4.575

5.  Neuroprotective effects of ebselen on experimental spinal cord injury in rats.

Authors:  Murat Kalayci; Omer Coskun; Ferda Cagavi; Mehmet Kanter; Ferah Armutcu; Sanser Gul; Bektas Acikgoz
Journal:  Neurochem Res       Date:  2005-03       Impact factor: 3.996

6.  Comparative studies on dicholesteroyl diselenide and diphenyl diselenide as antioxidant agents and their effect on the activities of Na+/K+ ATPase and delta-aminolevulinic acid dehydratase in the rat brain.

Authors:  Ige J Kade; Marcio W Paixão; Oscar E D Rodrigues; Nilda B V Barbosa; Antonio L Braga; Daiana S Avila; Cristina W Nogueira; João B T Rocha
Journal:  Neurochem Res       Date:  2007-08-21       Impact factor: 3.996

7.  Organochalcogens inhibit mitochondrial complexes I and II in rat brain: possible implications for neurotoxicity.

Authors:  Robson Luiz Puntel; Daniel Henrique Roos; Rodrigo Lopes Seeger; Michael Aschner; João Batista Teixeira Rocha
Journal:  Neurotox Res       Date:  2012-12-06       Impact factor: 3.911

8.  Ebselen attenuates oxidative stress-induced apoptosis via the inhibition of the c-Jun N-terminal kinase and activator protein-1 signalling pathway in PC12 cells.

Authors:  Masanori Yoshizumi; Toshiaki Kogame; Yuki Suzaki; Yoshiko Fujita; Moe Kyaw; Kazuyoshi Kirima; Keisuke Ishizawa; Koichiro Tsuchiya; Shoji Kagami; Toshiaki Tamaki
Journal:  Br J Pharmacol       Date:  2002-08       Impact factor: 8.739

9.  Inhibition of mitomycin C's aerobic toxicity by the seleno-organic antioxidant PZ-51.

Authors:  D L Gustafson; C A Pritsos
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

10.  Human blood cells support the reduction of low-density-lipoprotein-associated cholesteryl ester hydroperoxides by albumin-bound ebselen.

Authors:  J Christison; H Sies; R Stocker
Journal:  Biochem J       Date:  1994-12-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.